Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The secondary sialic acid-binding site (SBS) is a distinct, non-catalytic pocket located on the surface of the Influenza A virus neuraminidase (NA) protein, specifically within the N2, N9, and certain avian N1 subtypes (Vavricka et al., 2011, Nature Communications). Unlike the primary catalytic site which cleaves terminal sialic acid residues to facilitate viral release, the SBS binds sialic acid without hydrolyzing it (Uhlendorff et al., 2009, Journal of Virology). This site is believed to enhance the catalytic efficiency of the enzyme by recruiting complex glycans or assisting in the virus's initial attachment to host cells (Du et al., 2018, Journal of Virology). In the context of N2 neuraminidase, which is found in seasonal H3N2 influenza, the SBS plays a crucial role in the balance between hemagglutinin binding and neuraminidase cleavage (Mok et al., 2019, Journal of Virology). While current neuraminidase inhibitors like oseltamivir primarily target the catalytic site, the SBS represents an alternative therapeutic target to combat drug resistance (Zhu et al., 2012, Journal of Virology). Developing drugs that bind to the SBS could potentially overcome resistance seen in primary site mutations or provide a synergistic effect when used in combination with existing antivirals (Newstead et al., 2008, Journal of Molecular Biology). Research into multivalent sialic acid derivatives has shown promise in blocking this site to reduce viral fitness (Abed et al., 2015, Antiviral Research). The conservation of this site across various N2 strains makes it a stable target for broad-spectrum influenza therapy (Air, 2012, Influenza and Other Respiratory Viruses).
Inhibition of viral attachment and reduction of neuraminidase catalytic efficiency by preventing substrate recruitment to the primary active site (Vavricka et al., 2011, Nature Communications).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A virus neuraminidase N2 secondary sialic acid-binding site (N2 NA SBS).